Living at high altitude leads to longer life by changing metabolism – Earth.com

An estimated two million people worldwide reside above 4,500 meters (14,764 feet) in elevation, comparable to the heights of Mount Rainier, Mount Whitney, and numerous peaks in Colorado and Alaska. Intriguingly, these individuals have been observed to have lower rates of metabolic diseases, such as diabetes, coronary artery disease, hypercholesterolemia, and obesity. Researchers supported by the U.S. National Science Foundation at Gladstone Institutes have recently made strides in understanding this phenomenon.

The scientists discovered that chronic exposure to low oxygen levels, as experienced at high altitudes, altered the way mice metabolized sugars and fats. The study, published in the journal Cell Metabolism, offers insights into the metabolic differences in people living at high altitudes and suggests potential new treatments for metabolic diseases.

When an organism is exposed to chronically low levels of oxygen, different organs reshuffle their fuel sources and their energy-producing pathways, explained Isha Jain, senior author of the study. We hope these findings will help us identify metabolic switches that might be beneficial for metabolism even outside of low-oxygen environments.

At sea level, where a third of the global population resides, oxygen accounts for approximately 21% of the air we breathe. However, at elevations above 4,500 meters, oxygen makes up a mere 11% of the air. Despite these lower oxygen levels, known as hypoxia, people can adapt and thrive in these conditions.

Previous research on hypoxias impact has often been limited to isolated cells or cancerous tumors, which are commonly oxygen-deficient. Jains group aimed to investigate the long-term effects of hypoxia on organs throughout the body. They collaborated with colleagues at Gladstone and the University of California, San Francisco, to house adult mice in pressure chambers containing 21%, 11%, or 8% oxygen levels all of which are survivable by humans and mice.

Over three weeks, the researchers monitored the mices behavior, temperature, carbon dioxide levels, blood glucose levels, and used positron emission tomography (PET) scans to study nutrient consumption by different organs. In the initial days of hypoxia, mice in 11% or 8% oxygen environments exhibited reduced mobility and periods of complete stillness.

However, by the end of the third week, their movement patterns normalized. Likewise, their blood carbon dioxide levels, which typically decrease when mice or humans breathe faster to compensate for low oxygen, initially dropped but returned to normal levels by the end of the study.

The animals metabolism, on the other hand, appeared to be more permanently affected by hypoxia. Mice in hypoxic cages experienced decreases in blood glucose levels and body weight, with neither returning to pre-hypoxic levels.

These metabolic changes parallel those observed in humans living at high altitudes and are associated with a reduced risk of diseases, including cardiovascular disease. This understanding of hypoxias contribution could pave the way for developing new drugs that replicate these beneficial effects, offering hope for those suffering from metabolic diseases.

There is a growing body of research focused on understanding the biological processes of aging and developing strategies to extend human lifespan. Some of the prominent areas of research include:

These research areas, along with many others, represent the ongoing efforts to unravel the complex biology of aging and develop interventions that can promote healthy aging and extend human lifespan.

-

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

Continued here:
Living at high altitude leads to longer life by changing metabolism - Earth.com

Century Therapeutics Announces Leadership Changes – GlobeNewswire

Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer

Michael C. Diem, M.D., promoted to Chief Financial Officer

Hy Levitsky, M.D., rejoins as President of Research and Development

PHILADELPHIA, April 12, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Greg Russotti, Ph.D., as ad-interim Chief Executive Officer, effective April 11, 2023. Dr. Russotti, who has served as the Companys Chief Technology Officer since January 2020, is succeeding Lalo Flores, Ph.D., who has stepped down as Chief Executive Officer and as a member of the Companys Board of Directors to pursue other opportunities. In addition, effective April 11, 2023, Michael C. Diem, M.D., was promoted to the role of Chief Financial Officer, and Hy Levitsky, M.D., assumed his prior role as President of Research and Development.

The Board of Directors has commenced a search to identify a permanent Chief Executive Officer.

Lalo has played a key role in advancing Century, a premier cell therapy company, to where it is today. On behalf of the entire Board of Directors, we wish Lalo success and thank him for his service, said Joe Jimenez, Chairman of the Board. Greg is a true leader in the cell therapy space who we believe can build upon the Companys strong foundation with his significant clinical and commercial expertise. As Century enters an exciting new stage of growth, we look forward to continuing to leverage his extensive experience.

Mr. Jimenez added, Additionally, I would like to congratulate Mike Diem on his promotion to Chief Financial Officer, and I am pleased to welcome Hy Levitsky back to Century. Both Mike and Hy have been instrumental in Centurys success to date, and we look forward to their continued contributions as the Company advances its next generation platform and robust portfolio of cell therapy product candidates.

Greg Russotti, Ph.D., ad-interim Chief Executive Officer

Prior to joining Century, Dr. Russotti served as Vice President of Cell Therapy Development and Operations at Celgene. While at Celgene, he guided chemistry, manufacturing and controls efforts for five different cell therapy products to clinical-stage development. Dr. Russotti was also a leader in establishing in-house clinical manufacturing at Celgene, and in building Celgenes first commercial CAR T manufacturing facility. Prior to Celgene, he held various leadership roles at Merck Research Laboratories, developing vaccines and monoclonal antibodies for clinical and commercial manufacturing. He received his B.S. and M.S. degrees in Chemical Engineering from Rensselaer Polytechnic Institute, and his Ph.D. in Chemical and Biochemical Engineering from Rutgers University. Dr. Russotti has held a visiting professorship in Rutgers Biomedical Engineering department since 2008. He also serves as Industrial Executive Board Member of the Marcus Center for the Commercialization of Cell Therapies at Georgia Tech, and as an Executive Committee member of the National Science Foundation-funded Center for the Manufacturing of Advanced Therapeutics at Georgia Tech.

I am honored to assume this role, and I look forward to building upon our accomplishments to date to execute on our vision of delivering transformative allogeneic cell therapies to patients, said Dr Russotti. With a solid balance sheet, which we expect to fund operations into 2026, we believe we are well-positioned to continue to deliver on our key platform and program milestones.

Michael C. Diem, M.D., Chief Financial Officer

Dr. Diem, who joined Century in 2020, most recently served as the Companys Chief Business Officer. Prior to joining Century, he was Senior Vice President of Business and Corporate Development at Amicus Therapeutics, and prior to that, he held a similar role at Aevi Genomic Medicine. Earlier in his career, Dr. Diem was the Global Head of Corporate Strategy and Corporate Development at AstraZeneca, where he was responsible for mergers and acquisitions, divestitures, and managed the companys strategic investment activities and MedImmune Ventures. At GlaxoSmithKline (GSK), he led business development for the Companys rare disease business unit, and was also a partner in GSKs corporate venture firm, SR One, Limited. Dr. Diem obtained his M.D. from the Rutgers-Robert Wood Johnson Medical School, and an M.B.A. from Case Western Reserve University. He completed his medical training at Duke University and is a Kauffman Fellow.

Hy Levitsky, M.D., President of Research and Development

Dr. Levitsky previously served as Centurys President, Research and Development from 2019 until early 2023. Prior to joining the Company, he served as Executive Vice President and Chief Scientific Officer at Juno Therapeutics, Inc., and was also Head of Cancer Immunotherapy Experimental Medicine at F. Hoffmann-La Roche & Co. Previously, Dr. Levitsky was Professor of Oncology, Medicine, and Urology at The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, and the Scientific Director of the George Santos Bone Marrow Transplant Program at The Johns Hopkins University. He currently serves as a member of the Board of Directors of Replimune, Prokarium, and Carisma Therapeutics. Dr. Levitsky obtained his M.D. from The Johns Hopkins University School of Medicine.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit http://www.centurytx.com.

Century Therapeutics Forward-Looking Statement

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as may, might, will, should, expect, plan, aim, seek, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, forecast, potential or continue or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to obtain FDA acceptance for our future IND submissions and commence clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic, geopolitical issues and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the Risk Factors section of our most recent filings with the Securities and Exchange Commission and available at http://www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information: Company: Elizabeth Krutoholow investor.relations@centurytx.comInvestors and Media: Melissa Forst/Maghan Meyers century@argotpartners.com

See the rest here:
Century Therapeutics Announces Leadership Changes - GlobeNewswire

Sana Biotechnology (SANA) Announces Publication of Preclinical … – StreetInsider.com

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Science Translational Medicine has published a paper titled Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice. The paper details data from a series of ten in vivo experiments demonstrating the insulin-normalization activity, persistence, immune evasion, and lack of immunogenicity of human hypoimmune-modified islet cells, which cluster into effective endocrine organoids termed pseudo islets.

The replacement of defective or missing cells has been the goal for many diseases; however, immune rejection results in either systemic immunosuppression or therapeutic failure. Sanas proprietary hypoimmune platform was developed to solve this problem, said Steve Harr, Sanas President and CEO. The Science Translational Medicine paper details data demonstrating that hypoimmune pseudo islets developed with our hypoimmune technology survived and were able to reverse diabetes without any immunosuppression in humanized mice. Eliminating the need for insulin administration and reversing diabetes with normalization of blood glucose levels, and doing this without immunosuppression, would be a transformational advance for patients. Insights from this research along with an expected investigator-sponsored trial this year will inform the development plan for our SC451 product candidate in type 1 diabetes as we move forward with our goal of submitting an IND in 2024.

HIP Pancreatic Islet Cells Survive, Persist, and Escape Allogeneic RejectionSana generated human hypoimmune (HIP) pseudo islets (p-islets) and wild-type (wt) p-islets that were similar in size, cell type composition, and in vitro insulin secretion. The survival of the p-islets and their cell composition was assessed in immunocompetent, diabetic allogeneic humanized NSG-SGM3 mice. HIP or wt p-islet clusters were injected into the hindlimb muscle and were recovered on the same day or 7 or 28 days later. Wt p-islets could only be recovered on the same day and were fully rejected and dissolved at later time points. By contrast, the total cell count and cell composition of HIP islets did not change over time.

In another experiment, analyses were conducted a month following exposure to HIP and wt p-islets. There were no traces of wt p-islet grafts found in any animals after one month. Recovered splenocytes and serum from the wt p-islet treated animals showed markedly activated T cells (analyzed by ELISPOT) and donor-specific antibodies (analyzed by flow cytometry) against the grafts in the wt p-islet group, demonstrating a strong adaptive allogeneic immune response. By contrast, HIP p-islets showed the same morphology as before transplantation and contained alpha, beta, and delta cells. No immune cell infiltrate was observed in or around the HIP p-islet cells. Additionally, no adaptive allogeneic immune response was observed in humanized mice that received HIP p-islets and diabetes in these mice was alleviated. Confirmatory killing assays showed killing of wt p-islets and no killing of HIP p-islets.

HIP Islet Cells Control Insulin Similarly to Unedited Wild-Type Islet Cells in Immunodeficient MiceThe ability to control diabetes was assessed in immunodeficient NSG mice to remove the variable of immune rejection of allogeneic cells, enabling the comparison of wt and HIP p-islets. Diabetes was induced using streptozotocin (STZ) and all mice had fasting glucose concentrations >400 mg/dl on the day of p-islet graft transplantation. Wt and HIP p-islets both achieved glycemic control within approximately 2 weeks and generated similar c-peptide concentrations one months after transplantation. These functional data confirmed that HIP p-islet cells maintained endocrine function comparable to wt p-islets and showed unimpaired resilience toward the transplantation procedure.

HIP Islet Cells Ameliorate Diabetes in Models of Autoimmunity: NOD Mice as well as Humanized Autoimmune Mice The ability of HIP islet cells to avoid autoimmunity was assessed in two different models. The first set of experiments were in the NOD mouse, which is the primary animal model for studying autoimmunity in diabetes due to the similarities to the human disease. These studies demonstrate that mouse HIP p-islets survive while syngeneic p-islets are rejected due to autoimmune killing. Additionally, the impact of autoimmunity was studied in a humanized, diabetic autoimmune mouse. To generate a humanized, autoimmune mouse, immune cells and iPSCs were generated from PBMCs collected from a person with type 1 diabetes (T1D). Mice were engrafted with the T1D immune cells and diabetes was induced. The iPSCs were then either hypoimmune-modified or mock-modified, differentiated into islet cells, and transplanted into these immunocompetent, diabetic humanized mice to study autoimmunity in vivo. All HIP iPSC-derived p-islets survived and glycemic control was achieved in all recipients of HIP iPSC-derived p-islets. In contrast, all autologous, mock-modified iPSC-derived p-islets were fully rejected within 10 days due to autoimmunity and showed no effect on blood glucose, even temporarily, and animals had no detectable c-peptide after one month.

About Sanas Hypoimmune PlatformSanas hypoimmune platform is designed to create cells ex vivo that can hide from the patients immune system to enable the transplant of allogeneic cells without the need for immunosuppression. We are applying hypoimmune technology to both donor-derived allogeneic T cells, with the goal of making potent and persistent CAR T cells at scale, and pluripotent stem cells, which can then be differentiated into multiple cell types at scale. Preclinical data from a variety of cell types demonstrate that these transplanted allogeneic cells can evade both the innate and adaptive arms of the immune system while retaining their function. Our most advanced programs using hypoimmune technology include our allogeneic CAR T program targeting CD19+ cancers, our allogeneic CAR T program targeting CD22+ cancers, our allogeneic CAR T program targeting BCMA+ cancers, and our stem-cell derived pancreatic islet cell program for patients with type 1 diabetes.

About Sana BiotechnologySana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements about Sana Biotechnology, Inc. (the Company, we, us, or our) within the meaning of the federal securities laws, including those related to the companys vision, progress, and business plans; expectations for its development programs, product candidates, and technology platforms, including its pre-clinical, clinical, and regulatory development plans and timing expectations, including the expected timing of IND submissions for the Companys product candidates and indications for which the Company is developing its product candidates and for which such INDs will be submitted, and expected impact of data from pre-clinical studies of cells made using hypoimmune technology and from an investigator-sponsored trial using hypoimmune primary human islet cells in patients with type 1 diabetes (the IST), including the potential of pre-clinical data and the IST to provide insight that will inform development of its SC451 product candidate; expectations regarding the IST, including the ability to initiate the IST and expected timing, substance, and availability of data therefrom; the potential ability of the hypoimmune platform to create cells ex vivo that can hide from the patients immune system to enable the transplant of allogeneic cells without the need for immunosuppression, and the potential benefits associated therewith; and the potential ability to make potent and persistent CAR T cells at scale and of hypoimmune pluripotent stem cells to differentiate into multiple cell types at scale. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Companys strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as aim, anticipate, assume, believe, contemplate, continue, could, design, due, estimate, expect, goal, intend, may, objective, plan, positioned, potential, predict, seek, should, target, will, would and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Companys current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Companys actual results, please refer to the risk factors identified in the Companys Securities and Exchange Commission (SEC) reports, including but not limited to its Annual Report on Form 10-K dated March 16, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:Nicole Keith[emailprotected][emailprotected]

Source: Sana Biotechnology, Inc

See the article here:
Sana Biotechnology (SANA) Announces Publication of Preclinical ... - StreetInsider.com

From Petri Dishes to Profits: The Lucrative World of Cell Culture Media – GlobeNewswire

Westford, USA, April 10, 2023 (GLOBE NEWSWIRE) -- The market for Cell Culture Media is projected to grow at a CAGR of 13.2% during the forecast period (2022-2030) and is expected to reach USD 14.96 billion by 2030. The market growth is fueled by a rise in demand for biopharmaceuticals, increasing investments in research and development, technological advancements, a growing awareness of cell-based therapy, and an increasing demand for personalized medicine. SkyQuest reports that the global biopharmaceutical market is expected to grow at a CAGR of 9.7% and reach USD 485 billion by 2025. Additionally, 68% of experts attribute the rising adoption of cell-based assays in drug discovery and research as a driver for the cell culture media market.

SkyQuest's latest research findings suggest that the global monoclonal antibodies market is anticipated to grow at a CAGR of 13.5% and reach USD 262.5 billion by 2027, mainly due to the increasing demand for biopharmaceuticals and the development of advanced technologies for cell culture. Finally, reports indicate that 45% of experts consider the increasing demand for biologics and biosimilars as the primary driver for the cell culture media market.

Browse in-depth TOC on "Cell Culture Media Market.

Get a sample copy of this report:

https://www.skyquestt.com/sample-request/cell-culture-media-market

The significance of the cell culture media market lies in its provision of essential nutrients, growth factors, and other components crucial for cell growth and maintenance in diverse applications, including drug discovery, biopharmaceutical production, and tissue engineering. Rising biopharmaceutical demands and the emergence of advanced cell culture technologies spur this market's expansion.

Prominent Players in Cell Culture Media Market

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/cell-culture-media-market

Biopharmaceutical Production Segment to Drive Higher Sales due to the Rising demand for Biologics and Biosimilar, Single-use Technology, Regulatory Approvals

A recent analysis indicates that the Biopharmaceutical Production segment significantly contributed to the rapid development of the Cell Culture Media market in 2021, and this trend is expected to continue from 2022 to 2030. The demand for biologics and biosimilars, Single-use technology, and regulatory approvals drive this trend. The productivity of biopharmaceutical production has increased due to the use of advanced cell cultures technologies, such as perfusion and fed-batch processes. The Biotechnology Innovation Organization reports that over the past few decades, technological advancements have increased biopharmaceutical production's average yields by more than 100-fold. Additionally, according to SkyQuest reports, 94.7% of biopharmaceutical manufacturers are investing in advanced cell culture technologies to enhance productivity and reduce costs. The survey notes that the use of these technologies has led to a reduction in production costs by up to 30%.

According to research analysis, North America is expected to become a dominant player in the Cell Culture Media market from 2022 to 2030, with a projected growth rate of 9.82% during the forecast period, as reported by SkyQuest. The presence of many biopharmaceutical companies, well-established research infrastructure, and increasing demand for personalized medicine in the region drives this expansion. Recently, Catalent announced the expansion of its cell and gene therapy manufacturing facility in Maryland, which includes producing cell culture media and other critical raw materials, further contributing to the market growth in North America.

Reagents and Media Product Segment to Exhibit Strong Growth Due to Demand for Lightweight and Advanced Wheels and Brakes Systems

The Reagents and Media Product segment has emerged as the dominant method in the Cell Culture Media market in 2021 and is expected to retain its lead from 2022 to 2030, driven by the increasing demand for biologics and biosimilars, the growth of the biopharmaceutical industry, and the development of advanced cell culture technologies. SkyQuest reports that the reagents and media product segment also benefits from the growing demand for automation and high-throughput screening in drug discovery. The global high-throughput screening market is expected to grow at a CAGR of 7.8% during the forecast period due to the increasing demand for automated systems and the development of novel screening technologies.

The Asia Pacific region has emerged as a significant force in the Cell Culture Media market and is expected to retain its leading position by 2030, as forecasted by SkyQuest, with a projected CAGR of 12.97% during the forecast period. This expansion can be attributed to the growing number of pharmaceutical companies and increasing investment in regional research and development.

A comprehensive analysis of the major players in the Cell Culture Media market has been recently conducted in a report. The report encompasses various aspects, including collaborations, mergers, innovative business policies, and strategies, providing valuable insights into key trends and breakthroughs in the market. Furthermore, the report scrutinizes the market share of the top segments and presents a detailed geographic analysis. Lastly, the report highlights the major players in the industry and their endeavors to develop innovative solutions to cater to the growing demand.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/cell-culture-media-market

Key Developments in Cell Culture Media Market

Key Questions Answered in Cell Culture Media Market Report

Related Reports in SkyQuests Library:

Global Research Antibodies and Reagents Market

Global Targeted Therapeutics Market

Global IVD Quality Control Market

Global Microbubbles/Ultrasound Contrast Agents Market

Global Yeast Extracts For Animal Feed Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter

See the original post here:
From Petri Dishes to Profits: The Lucrative World of Cell Culture Media - GlobeNewswire

Asia Pacific Stem Cell Therapy Market Size, Demand, Share, Revenue, Key Players, Growth, and Forecast 2023 to – openPR

Astute Analytica's recently published report on the Asia Pacific Stem Cell Therapy Market offers the latest data and determines growth prospects and challenges. A tool for evaluating the potential for new goods and services is the constraints and opportunity analysis. This aids businesses in locating and forecasting market opportunities.

Request Of this Sample Report Here- https://www.astuteanalytica.com/request-sample/asia-pacific-stem-cell-therapy-market

The study also contains a compilation of qualitative and quantitative evaluations made by subject-matter experts in their fields as well as representatives from various industries found all along the supply chain.

The Asia Pacific stem cell therapy market is poised for substantial growth in the coming years, with a projected compound annual growth rate (CAGR) of 10.29% between 2023 and 2031. This growth is expected to drive the market value up to US$ 3,420.05 Mn by 2031, following a successful revenue performance of US$ 1,453.61 Mn in 2022.

The paper discusses further findings that researchers made based on the comprehensive data and also offers information on the state of the market. The paper discusses kinds and applications based on various nations and important locations. The market's most active companies are described in detail with regard to attributes like corporate portfolio, business strategy, financial overview, recent developments, and industry share.

Leading Companies

AlloSourceAnterogen Co. Ltd.Arce TherapeuticsAstellas Pharma IncBiogend TherapeuticsBiorestorative Therapies Inc.Brainstorm Cell Limited.Cellular Biomedicine GroupCORESTEMFujifilm Holding CorporationHolostem Terapie Avanzate SrlJCR Pharmaceuticals Co. Ltd.Kangstem BiotechMEDIPOST Co. Ltd.Mesoblast LtdPersonalized Stem CellsPELL Biotech Co., Ltd.Pluristem Inc.RTI SurgicalSartorius AGSewon CellontechSmith+NephewSTEMPEUTICS RESEARCH PVT LTD.Takeda Pharmaceutical Company LimitedVericel CorpOther Prominent PlayersMore Full Report Here- https://www.astuteanalytica.com/industry-report/asia-pacific-stem-cell-therapy-market

We continuously monitor the direct impact COVID-19 (Update Omicron mutations study) has on the market, in addition to the indirect influence of related industries. The report will contain the observations.

The geographical regions are divided into several major categories for production, consumption, revenue (in US dollars), and market share in this analysis. We'll discuss the predicted growth of the market in this region between 2021 and 2031.

Segmentation Overview

The Asia Pacific stem cell therapy market is segmented based on therapy type, product, cell source, technology, application and end user.

By Therapy Type segmented, the Asia Pacific stem cell therapy market is sub-segmented into:

Autologous Stem Cell TherapyAllogeneic Stem Cell TherapyBy Product segment, the Asia Pacific stem cell therapy market is sub-segmented into:

Adult Stem Cells (ASCs)Human Embryonic Stem Cells (HESCs)Induced Pluripotent Stem Cells (iPSCs)Very Small Embryonic Like Stem CellsBy Cell source segment, the Asia Pacific stem cell therapy market is sub-segmented into:

Adipose tissue derived MSCsBone marrow derived MSCsPlacental/umbilical cord derived MSCsOther Cell SourcesBy technology segment, the Asia Pacific stem cell therapy market is sub-segmented into:

Cell AcquisitionCell ProductionCryopreservationExpansion and Sub-CultureBy application segment, the Asia Pacific stem cell therapy market is sub-segmented into:

Musculoskeletal DisordersWounds and InjuriesAcute Graft-Versus-Host Disease (AGVHD)SurgeriesGastrointestinal DiseasesCardiovascular DiseasesInflammatory & Autoimmune DiseasesNeurological DisordersOthersBy end user segment, the Asia Pacific stem cell therapy market is sub-segmented into:

HospitalsResearch institutesSurgical institutesOthersBy country, the Asia Pacific stem cell therapy market is sub-segmented into:

ChinaIndiaJapanAustralia & New ZealandASEANTaiwanSouth KoreaRest of Asia Pacific

Access Sample Report Here- https://www.astuteanalytica.com/request-sample/asia-pacific-stem-cell-therapy-market

About Astute Analytica:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Get in touch with us:

Phone number: +18884296757

Email: sales@astuteanalytica.com

Visit our website: https://www.astuteanalytica.com/

This release was published on openPR.

Read the original here:
Asia Pacific Stem Cell Therapy Market Size, Demand, Share, Revenue, Key Players, Growth, and Forecast 2023 to - openPR

The Explorers: A Passion for Science Leads to New Territory – University of California San Diego

Unusual Breadth

This quest soon led them to seek out real-world problems that could have a bigger impact on peoples lives than basic science. They moved to the West Coast, where they pursued a mix of research and development jobs in biotechincluding at Amgen and Invitrogen (acquired by Thermo Fisher)and at universities including UC Berkeley (Molokanova), UC San Diego and Stanford University (Savtchenko).

These experiences working at intersection of physics and biology coupled with decades of work across multiple scenarios in academics and industry gave the couple a unique perspective on many of the biggest problems in neuroscience and drug discovery, as well as the business processes that helped or hindered progress.

So, as they discussed whether to start their own companies, they didnt have to deliberate for long.

It was pretty clear to me that the science was coming along nicely, and that our contribution [as entrepreneurs] would be serious, meaningful, said Savtchenko.

One major challenge the pair had observed in the biotech industry involved initial testing of potential drug compoundsresults that informed whether compounds would be pursued or discarded from consideration for further development as medicines.

Savtchenko noted that biotech and pharmaceutical companies spend billions of dollars on screening drug compounds for safety and activityin vitro(in cell culture), yet the environment in plastic cell culture dishes drastically differs from the human body, especially for nerve cells (a.k.a. neurons) and heart cells (a.k.a. cardiomyocytes).

The biggest difference between neurons in the brain and neurons in a cell culture dish is whether they receive external input or not, Savtchenko explained. From the very first moment of our existence, it is normal and, in fact, necessary for our brains to be constantly bombarded by various signals (e.g., stimuli from sight, hearing, feeling, tasting)the results determine our development, define our individual personalities and, often, affect our health.

He continued, To discover drugs that can fix aberrations in brain activity and heal a patient, it is imperative to test the drug effects on functionally active, input-receiving, dynamic response-producing neurons. Otherwise, clinical studies in human patients might produce drastically different outcomes than priorin vitrostudiesresulting in failed projects, loss of multibillion dollar investments, and disappointment for millions of patients.

The development of medication that could affect the heart faces similar challenges. Testing for drug cardiotoxicity is often performed in highly artificial conditionsin an electrically insulated culture dish of human stem-cell derived cardiomyocytes, spontaneously contracting at a single frequency. In real-life, adult heart rates can vary almost two-fold over the course of a day in response to changing conditions.

Highlighting the importance of such testing, in recent decades several blockbuster drugs have been removed from the market because they were linked to irregular heartbeat, accounting for 30% of all post-approval withdrawals.

Savtchenko and Molokanova wanted to find a way to safely and reliably stimulate cells in a dish while testing their response in the presence of drug compounds so that the results of these screening studies would better predict the drugs affect in humans. Reaching this goal would mean that fewer drugs would fail at the last stages of drug discovery process, resulting in safer, more efficient, and less expensive drugs.

After her industry experience working with different materials, including semiconductor quantum dots, to stimulate cells in culture, Molokanova hit on the idea to harness the unique properties of a new two-dimensional carbon allotrope, graphene.

Graphene had been discovered by Andre GeimandKonstantin Novoselov (coincidentally fellow alumni of Savtchenkos alma mater, MIPT), who were awarded the 2010 Nobel Prize in Physics for this finding. In the Nobel announcement, the Royal Swedish Academy of Sciencesdescribedgraphene as a thin flake of ordinary carbon, just one atom thick [with] exceptional properties that originate from the remarkable world of quantum physics.

Continued here:
The Explorers: A Passion for Science Leads to New Territory - University of California San Diego

With A CAGR of 4.9%, Research Antibodies Market Size Worth USD 2.17 Billion By 2030 | Emergen Research – EIN News

Research Antibodies Market Trends An increase in research and development (R&D) activities related to the fields of neurobiology

Emergen Research

The global research antibodies market is projected to be worth USD 5,325.8 Million by 2027, according to a current analysis by Emergen Research. The market for research antibodies is witnessing a high demand due to its growing application in neurobiology, infectious diseases, oncology, stem cells, and immunology, among others. Increased investments in research in the field of stem cells is also a crucial growth factor of the Research Antibodies market.

To Get Free Sample PDF Copy of This Report

https://www.emergenresearch.com/request-sample/192

Research Antibodies Market, By Antibody Type (Monoclonal and Polyclonal), By Antibody Type (Primary Antibodies and Secondary Antibodies), By Application, By Technology, By End-use, and By Region Forecast to 2030. An increase in research and development (R&D) activities related to the fields of neurobiology, oncology and stem cell research, the increasing incidence of cancer and infectious diseases, and the growing demand from the biopharmaceutical industry for these antibiotics are the main drivers of the market. increase the revenue. Research antibodies are antibodies that can bind to specific molecules, which are used as basic detection tools needed in scientific research and are also important tools for studying protein function in cell.

Key Players Included in this report are:

Lonza Group, Becton, Dickinson, and Company, Agilent Technologies, Abcam PLC, PerkinElmer Inc., Bio-Rad Laboratories, Merck Millipore, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Cell Signaling Technology Inc.

What can be explored with the Research Antibodies Market Study?

Gain Market Understanding

Identify Growth Opportunities

Analyze and Measure the Global Research Antibodies Market by Identifying Investment across various Industry Verticals

Understand the Trends that will drive Future Changes in Research Antibodies Market

Understand the Competitive Scenarios

Track Right Markets

Identify the Right Verticals

Quick Buy Research Antibodies Market

https://www.emergenresearch.com/select-license/192

Some Key Highlights from the Report

The research antibodies market has been divided into hospitals, dental offices, and other end-uses. Over the projected period, it is anticipated that the dental clinics segment will contribute the most to total revenue. They meet a variety of client needs and offer the necessary knowledge, along with a vast array of technologically cutting-edge tools and supplies, to perform any orthodontic procedure. Better patient reimbursement dental policies are available at dental clinics. Furthermore, the significant market share of dental clinics is caused by an increase in orthodontists' private practises. Some major companies in the global research antibodies market report include Merck KGaA, Johnson & Johnson Services, Inc., Eli Lilly and Company., Bio-Rad Laboratories, Inc., Cell Signalling Technology, Inc., PerkinElmer Inc., ROCKLAND IMMUNOCHEMICALS, INC., Novartis AG, BD, and Abcam plc. Market Segmentation Analysis

Players can concentrate on high-growth regions and, if necessary, modify their business plan according to the research report. The Research Antibodies Market is divided into a variety of categories, uses, and geographical areas. Players gain from the report's regional segmentation research since it offers pertinent data and insights into important geographic marketplaces.

Antibody Type Outlook (Revenue, USD Million; 2017-2027) Monoclonal Polyclonal Product Outlook (Revenue, USD Million; 2017-2027) Primary Antibodies Secondary Antibodies COVID-19 Impact Analysis

The post-COVID-19 phase has undergone substantial change, and Research Antibodies Market research highlights the opportunities and difficulties that still exist. This study report thoroughly examines the effects of the COVID-19 pandemic on the global economy and post-pandemic market behaviour.

Ask for Customization

https://www.emergenresearch.com/request-for-customization/192

Regional Outlook

We carefully examined each division, regional classification, national study, and subject-specific data set during the market research. This Research Antibodies Market research report's goal is to look at growth patterns, promising futures, important obstacles, and expected results. Information on significant market participants, strategic alliances, plans, new product launches, and joint ventures are all included in the research.

Research Methodology

Emergen Research follows a cohesive methodology to reduce the residual errors to a minimum level by refining the scope, validating through primary insights, and nurturing the in-house database on a regular basis. A dynamic model is formulated to capture the regular fluctuations in the market and thereby, being updated with any shifts in the market dynamics.

PRIMARY RESEARCH MODEL

Post conglomeration of the data obtained through secondary research; a validation process is initiated to verify the numbers or figures. This process is usually performed by having a detailed discussion with the industry experts. Discussions with the subject matter experts were conducted to obtain quantitative and qualitative information and validate our market research findings.

Key Reasons to Purchase Research Antibodies Market Report

The reader will be in a position to comprehend and react to marketing strategies like using strengths and conducting a SWOT analysis.

The research looks into the dynamics of the target market and how the conflict between Russia and Ukraine has affected it.

Look Over transcripts provided by Emergen Research

Artificial Neural Network Market

https://usahealthnewswire.blogspot.com/2023/04/artificial-neural-network-market-global.html

Nebulizers Market

https://usahealthnewswire.blogspot.com/2023/04/nebulizers-market-size-share-price.html

Routing Market

https://usahealthnewswire.blogspot.com/2023/04/routing-market-global-industry-size.html

Industrial Robotics Market

https://usahealthnewswire.blogspot.com/2023/04/industrial-robotics-market-global.html

Thank you for reading our report. Please get in touch with us if you have any query regarding the report or its customization. Our team will ensure the report is best suited to your needs.

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Eric LeeEmergen Research+91 90210 91709sales@emergenresearch.comVisit us on social media:FacebookTwitterLinkedIn

Read this article:
With A CAGR of 4.9%, Research Antibodies Market Size Worth USD 2.17 Billion By 2030 | Emergen Research - EIN News

EW GROUP SHINES AT 12TH A4M SYMPOSIUM 2023 & – InvestorsObserver

BANGKOK , April 11, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group) made a successful showing at an exclusive event, the 12 th A4M Symposium 2023, which was held in Centara, Bangkok , 16 th -19 th February 2023 .

The two-day A4M Symposium, commenced with a welcome ceremony featuring Dr. Manus Potaporn (Deputy Director General of Medical Services Department, Thailand ) as a Guest of Honour, hosted by Prof. Dr. Mike Chan (A4M Thailand President), Dr. Jakkriss Bumisawasdi (A4M Thailand Honorary President), and Dr. Robert Goldman (A4M Founder).

On February 19 , European Wellness Academie (EWA), a non-profitable educational arm of EW Group, brought an exclusive workshop, "All-On Bioregen Optimization," to explore the world of anti-aging and regenerative medicine, featured some of the world's leading anti-aging experts.

Prof. Dr. Mike Chan , presented his two topics, "The Application of Regenerative Precursor Stem Cells, Peptides & Exosomes in Precision Medicine" and "Phyto-Myco-based Nano Organo Peptides: A New Trend in Precision Medicine."

"Precision Medicine in Age Reversal," which brought together the anti-aging and wellness industries on a single platform to achieve Precision Medicine's goals, which are patient-centred, may divide patients into subgroups based on their illness vulnerability, prognosis, or response to a specific treatment. It is devised and administered after comprehensive diagnostics utilizing Panomic Analysis and System Biology to analyse the patient's state at a molecular level and apply targeted therapies to address illness progression.

Anti-aging medicine aims to improve human ageing and maximize physical and mental well-being. Scientific data and medical journals supported the model's focus on Advanced Clinical Preventive and Regenerative Medicine.

The involvement of the healthcare and wellness industries will have a significant influence on the anti-aging sector for many years to come. Yet, by fact these sectors worked together to improve the quality of life for individuals and will contribute to defining the very future of modern medicine.

European Wellness Biomedical Group

An award-winning European group, most renowned for its pioneering development in organ-specific precursor (progenitor) stem cell therapeutics, biological and synthetic peptides, biological regenerative medicine, immunotherapies, and nutraceutical and cosmeceuticals.

EW Group's multinational business divisions include research and developments, bio-manufacturing, biomedical academies, hospital and wellness centres and nutraceutical product distribution across 80 countries worldwide. EW Group also owns and operates a growing network of internationally accredited Hospital and Medical Centres specializing in Regenerative Bio-Medicine and luxury Wellness Centres globally. EW Group is headquartered in Germany and Malaysia ( Asia Pacific ) with research vested in Germany , Switzerland , Czech Republic and United Kingdom .

Home

Media Contact: Ferellica Anne Martin +6088 448 989 (Ext: 337) media@european-wellness.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/ew-group-shines-at-12th-a4m-symposium-2023--all-on-bioregen-optimization-workshop-301796266.html

SOURCE European Wellness Biomedical Group

Continue reading here:
EW GROUP SHINES AT 12TH A4M SYMPOSIUM 2023 & - InvestorsObserver

Jasper Therapeutics Appoints David Hinds as Senior Vice President … – GlobeNewswire

REDWOOD CITY, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of David Hinds, as the Companys Senior Vice President, Development Operations.

We are pleased to welcome David to our team. His outstanding track record in setting strategic directions for clinical research and operations will allow us to effectively advance our development programs for briquilimab, said Ronald Martell, President and Chief Executive Officer of Jasper. As we navigate through a critical phase in our advancement of this promising asset, Davids leadership will be instrumental in rapidly progressing briquilimab in chronic spontaneous urticaria and initiating chronic lower-risk MDS study, all while maintaining momentum in the SCID, Fanconi Anemia, and sickle cell disease transplant studies recruitment.

Mr. Hinds brings more than 25 years of experience in operations and clinical program development across multiple therapeutic areas, all phases of development, and all regions of the world. Throughout his career, Mr. Hinds held a number of leadership roles, most recently as Vice President and General Partner at ICON plc, the worlds leading clinical research organization. Previously he served as Vice President, Clinical Operations at PellePharm and Tioma Therapeutics. He also led the clinical development and operations strategy at Alios Biopharma, Takeda, Clinipace, Exelixis, Kai Pharmaceuticals, Genentech, Genitope Corporation, and Intermune. He directly contributed to the success of global products including Rituxan, Adcetris, Velcade, Truvada, Orbactiv, Pirfenidone, and Celebrex. Mr. Hinds earned a Masters of Business Administration from Moore School of Business, University of South Carolina, and a Bachelor of Science in Biology at The Citadel The Military College of South Carolina.

I am thrilled to join the Jasper team at such an exciting time as the Company expands the development of briquilimab into chronic mast cell diseases and advances its novel conditioning approach for stem cell transplant, said Mr. Hinds. I look forward to contributing to the Jasper team by leveraging all the hard work that has been accomplished to date and executing on near-term clinical milestones.

About Jasper

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us atwww.jaspertherapeutics.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimabs potential, including with respect to its potential to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes as well as novel stem cell transplant conditioning regimes, its potential to address a variety of patient populations by targeting c-Kit expressed on stem cells and mast cells and its efficacy and safety profile, pathways to market, the expansion of briquilimab development, Jaspers expectations regarding the timing of clinical trials and recruitment for clinical trials and Jaspers expectations regarding its cash and cash equivalents and planned operating and capital expenditures. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jaspers product candidates may not be beneficial to patients or successfully commercialized; patients willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jaspers business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jaspers business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jaspers filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022. If any of these risks materialize or Jaspers assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jaspers assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

John Mullaly (investors)LifeSci Advisors617-429-3548jmullaly@lifesciadvisors.com

Jeet Mahal (investors)Jasper Therapeutics650-549-1403jmahal@jaspertherapeutics.com

Lauren Barbiero (media)Real Chemistry646-564-2156lbarbiero@realchemistry.com

Read more:
Jasper Therapeutics Appoints David Hinds as Senior Vice President ... - GlobeNewswire